Buy Sustanon (Testosterone Mix) 250 mg/ml – HilmaBioCare EU

Product Overview & Pharmaceutical Specifications

Sustanon 250 is an injectable testosterone formulation containing four testosterone esters in an oil-based sterile solution for intramuscular administration.

Pharmaceutical Specifications

• Product: Sustanon (Testosterone Mix) 250
• Active pharmaceutical ingredients:
  • Testosterone decanoate – 100 mg
  • Testosterone phenylpropionate – 60 mg
  • Testosterone isocaproate – 60 mg
  • Testosterone propionate – 30 mg
• Total strength: 250 mg/ml
• Dosage form: Injectable, oil-based sterile solution
• Route of administration: Intramuscular injection
• Pack size: 10 ml multiple-dose vial
• CAS number supplied: 5721-91-5
• Molecular formula supplied: C₁₉H₂₈O₂
• Molecular weight supplied: 288.4244 g/mol
• Manufacturer: Hilma Biocare
• Market status supplied: Prescription
• Storage: 15–25°C, in a cool, dry place; protect from light

Formulation

Sustanon 250 combines four testosterone esters with different ester characteristics. According to the supplied product information, this formulation is intended to provide a rapid increase in serum testosterone following intramuscular administration followed by sustained elevation.

Packaging

The supplied presentation is Sustanon 250 mg/ml in a 10 ml multiple-dose vial.

Pharmacology & Product Information

Pharmacological Class

Sustanon 250 contains testosterone esters and belongs to the class of androgenic and anabolic steroid hormones.

Testosterone and its active metabolites are involved in the development and maintenance of male reproductive tissues and secondary sexual characteristics. The supplied information also describes testosterone as having anabolic effects involving protein metabolism and nitrogen balance.

Mechanism of Action

Following intramuscular administration, testosterone esters are slowly absorbed from the injection site and subsequently hydrolysed in plasma to testosterone.

Circulating testosterone is primarily transported in serum bound to sex hormone-binding globulin (SHBG) and albumin. Testosterone can be metabolised through different pathways, with dihydrotestosterone (DHT) and estradiol identified in the supplied information as important active metabolites.

Exogenous testosterone may exert feedback effects on the hypothalamic-pituitary-gonadal axis. Testosterone administration can inhibit endogenous testosterone production through suppression of pituitary luteinizing hormone (LH), while higher androgen exposure may also suppress spermatogenesis through feedback inhibition of follicle-stimulating hormone (FSH).

Pharmacokinetic Information

The supplied product information states that serum testosterone increases rapidly within approximately 24 hours following intramuscular administration and remains elevated for approximately 7–10 days.

Esterification of testosterone increases its lipid solubility and prolongs its activity. Following intramuscular administration in an oily vehicle, the testosterone ester is slowly absorbed into circulation and hydrolysed to testosterone.

Documented Pharmaceutical Applications

According to the supplied source information, Sustanon 250 is indicated for testosterone replacement therapy in adult males with conditions associated with deficiency or absence of endogenous testosterone.

The supplied indications include:

• Primary hypogonadism, including testicular failure associated with conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy.
• Hypogonadotropic hypogonadism, including idiopathic gonadotropin or LHRH deficiency and pituitary-hypothalamic injury associated with tumors, trauma, or radiation.

These indications reflect the supplied product information and should not be interpreted as confirmation of marketing authorization in every EU member state.

Adverse Reactions & Safety Information

The supplied product information reports the following potential adverse reactions:

Male Reproductive System

• Gynecomastia
• Excessive frequency or duration of penile erections
• Oligospermia

Skin and Appendages

• Hirsutism
• Male pattern baldness
• Acne

Fluid and Electrolyte Disturbances

• Sodium retention
• Chloride retention
• Water retention
• Potassium retention
• Calcium retention
• Inorganic phosphate retention

Gastrointestinal and Hepatic

• Nausea
• Cholestatic jaundice
• Alterations in liver function tests
• Hepatocellular neoplasms
• Peliosis hepatis
• Hepatic adenomas
• Cholestatic hepatitis

Hematologic

• Suppression of clotting factors II, V, VII and X
• Increased bleeding risk in patients receiving anticoagulant therapy

Nervous System

• Increased or decreased libido
• Headache
• Anxiety
• Depression
• Generalized paresthesia

Other Reported Effects

• Serum lipid changes
• Hypercalcaemia
• Hypertension
• Oedema
• Priapism
• Potentiation of sleep apnea

Contraindications

According to the supplied product information, Sustanon 250 should not be used in patients with:

• Known hypersensitivity to any ingredient
• Known or suspected carcinoma of the breast, testis, or prostate
• Severe heart disease
• Liver disease
• Kidney disease
• A history of epilepsy

The supplied information also states that testosterone-containing products should not be used in women because of the potential for virilization and fetal harm.

Precautions

Androgens may alter serum cholesterol concentrations. Caution is therefore advised in patients with a history of myocardial infarction or coronary artery disease.

Patients receiving oral anticoagulant therapy require close monitoring, particularly when androgen therapy is initiated or discontinued.

In patients with diabetes mellitus, androgens may affect the metabolism of oral hypoglycaemic agents or alter insulin sensitivity. Adjustment of antidiabetic treatment may therefore be required under qualified medical supervision.

Patient Monitoring

The supplied information recommends monitoring parameters including:

• Total cholesterol
• HDL
• LDL
• Triglycerides (TG)
• Haemoglobin
• Haematocrit
• Hepatic function tests, including AST and ALT
• Prostate-specific antigen (PSA)
• Total, free and bioavailable testosterone
• Dihydrotestosterone (DHT)
• Estradiol

For male patients over 40, the supplied information recommends evaluation of the prostate and PSA before androgen use, with periodic prostate assessment during androgen therapy, particularly where urinary difficulties or changes in voiding habits occur.

Drug Interaction Information

The supplied product information identifies potential interactions with:

• Oral anticoagulants: androgen therapy may increase sensitivity to anticoagulants and requires appropriate monitoring.
• Oral hypoglycaemic agents and insulin: testosterone may affect glucose metabolism and insulin sensitivity.

Patients taking medicines that may interact with testosterone should follow the advice of a qualified healthcare professional.

Dosage and Administration

The supplied source states:

Adult male: 150–300 mg administered intramuscularly every 1–2 weeks or as directed by a physician.

Administration should follow the official prescribing information applicable to the product and the instructions of a qualified healthcare professional.

Presentation

Sustanon 250 mg/ml, 10 ml multiple-dose vial.

Storage Conditions

Store at 15–25°C in a cool, dry place.

Protect from light.

Scientific & Regulatory References

No PubMed references, DOI references, clinical literature citations, manufacturer documentation, or official regulatory source documents were supplied with the product data.

Accordingly, no external scientific or regulatory citations have been added.

The supplied product data identifies the market status as Prescription. This information does not independently establish marketing authorization or legal sale status in every EU member state.

Pharmaceutical Terms & Compliance

Important: This product information is provided for informational purposes only and does not replace professional medical advice. Always consult a qualified healthcare professional and follow the official product information, prescribing instructions and applicable regulations in your country.

The supplied source identifies Sustanon 250 as a prescription product. Regulatory authorization, prescribing requirements and lawful availability may differ between European countries. Customers should verify the applicable requirements with the relevant national competent authority and a qualified healthcare professional.